Barclays’s Passage Bio PASG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$963 Buy
214
+2
+0.9% +$9 ﹤0.01% 4973
2026
Q2
$1.04K Hold
212
– – ﹤0.01% 4929
2026
Q1
$1.66K Hold
212
– – ﹤0.01% 4868
2025
Q4
$2.5K Hold
212
– – ﹤0.01% 5032
2025
Q3
$1.7K Buy
212
+1
+0.5% +$7 ﹤0.01% 5155
2025
Q2
$1.69K Hold
211
– – ﹤0.01% 5046
2025
Q1
$1.49K Sell
211
-447
-68% -$4.83K ﹤0.01% 5018
2024
Q4
$7.46K Hold
658
– – ﹤0.01% 5023
2024
Q3
$9.21K Hold
658
– – ﹤0.01% 4982
2024
Q2
$10.4K Hold
658
– – ﹤0.01% 4514
2024
Q1
$17.8K Hold
658
– – ﹤0.01% 4766
2023
Q4
$13.3K Hold
658
– – ﹤0.01% 4949
2023
Q3
$8.66K Hold
658
– – ﹤0.01% 4324
2023
Q2
$12.4K Hold
658
– – ﹤0.01% 4204
2023
Q1
$12.6K Hold
658
– – ﹤0.01% 4718
2022
Q4
$18.2K Hold
658
– – ﹤0.01% 4825
2022
Q3
$16K Sell
658
-20
-3% -$788 ﹤0.01% 4142
2022
Q2
$32K Sell
678
-319
-32% -$14.9K ﹤0.01% 4220
2022
Q1
$62K Buy
+997
New +$82.2K ﹤0.01% 4022

Other funds holding PASG

Barclays's PASG Position: Q3 2026 in Review

Barclays increased its Passage Bio (PASG) stake by 0.94% in Q3 2026, buying an estimated $9 and bringing the position to 214 shares worth $963. The position accounts for ﹤0.01% of the portfolio, ranked #4973.

Barclays first reported a position in PASG in Q1 2022 and has held it in 19 quarters since. The position peaked at $62K in Q1 2022. 29 funds tracked by Wall St. Rank hold PASG as of Q3 2026.

  • Barclays held 214 shares of Passage Bio worth $963 as of Q3 2026.
  • Barclays bought 2 Passage Bio shares in Q3 2026, an estimated $9.
  • Passage Bio made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4973 holding.
  • Barclays first reported a position in Passage Bio in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Passage Bio position peaked at $62K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Passage Bio as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.